Mercury Bio is an intracellular immunotherapeutics biotech company in Santa Fe, New Mexico, founded in 2021. We’re focused on the central nervous system, with lead programs in Parkinson’s and Alzheimer’s.

Our technology, MB-TIP™ (Targeting Intracellular Pathologies), reaches where these diseases begin: inside the neuron. Our patented, engineered extracellular vesicles yEVs™ cross the blood-brain barrier, enter the cytoplasm, avoid endosomal trapping, and deliver the cargo - proteins, small molecules, or RNA directly inside the cell.

That’s what makes disease modification possible. In Parkinson’s and Alzheimer’s, the proteins driving the disease misfold and accumulate inside the neuron, where the damage begins. Reaching that compartment opens up a broad set of targets.

Mercury Bio is built on a 14-patent-family IP portfolio and led by co-founders Bruce McCormick, Dana Barnard, and Dr. Richard Sayre with pharma/biotech executive Casey Perkins. The team brings decades of experience across drug discovery, development, and commercialization.

Mercury Bio

Org chart

Teams

Offices

Mercury Bio

Org chart

Teams

Offices

Related companies